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                WITH THREE RADIOIMMUNOASSY KITS
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Tsuguo UMEHARA and Toshie KuRotiATA
From the Department ef Urolog］， SappDro Medical College
    The enzyme assay for acid phosphatase and even for L－tartrate labile acid phosphatase is not
specific for that df the p’r6S’tate origin： The’radioimmunoassaY has recently been developed to detect
the enzymg ．rpore sp． egific tg．thg prostate． We ．garrlgd out the investigations of the fundamental char－
acters and clinical usefulness in three commercial kits （Eiken’s kit， Clinical Assays’ kit and Mallinckrodt’s
kit）． The results were as ’followed．
    1） The repreducibility of・・their standard curves using three kits showed the satisfact6ry results
with the straight lines in them． CoeMcients of variation within assay was minimum among three
kits （2．10／，一一14．5e／，）． Coe’fHcient between assays was also minimum in them （6．2N14．JPO／，）． The
dilution tests in them were satisfactory． The recovery tests in three kits revealed the recoVered rate
to be almost 1000／．． These results in this fundamental study showed that three kits were usefu1 in
clinical practice．
    2） The・ correlation in three kits was investigated by the measurement of Eiken’s standard sera
with． Clin． ical Assays’ and Mallinckrodt’s kit． ’This ’sihowed the good correlation in each instance．
For the． further investigation of their correlation， 41 samples which were below 3．0 ng／ml in Eiken’s
kit， werd rneaS“．． red 1． y Cli’piqa．1 Assays’．and iMallinckrodt’s kit． This， however， did not reveal the
good corr¢latio．n qach other． Whi］e，． comparing the rati6 of sarr｝ples within normal range in three
k量ts，．@n6．唐奄№獅奄?奄Uahf．δi蝕駕卓¢幅9．obsefved．．．With the same comparison between E呈ken，s「and Clinical
Assays” kit， and between Eiken’s and Mallinckrodt’s kit， these raeios were almost identical in the samples
with．．B．P．H． and non－prostatic dise．ases． These rcsults have led us to the conclusion that the low degree
of correlation． in low qQ．nc．．entratio4 samples in threekit＄ have not always produced the serious problems
in the clinical practice． ’ Of cQurse， the further fundamental investigations will be necessary in the
selection of PAP sources and methods of PAP purification， which may be related to the differences
of PAP level in three kits．
    3） The correlation of PAP level measured by the radioimmunoassay and that by the enzyme
assay 一was good ．on the whole （Eiken’s kit： r＝＝O．69， Clinical Assays’ kit： r＝＝O．85 and ．Mallincktodt’s
kit：rrO．71）， whi，le this was．． hot true in．the．low concentrati叩samples．
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    4） PAP was measured by three kits in 427 samples from normal male and female adults， and
those with various urological diseases （190 cases in Eiken’s kit， 141 cases in Clinical Assays’ kit and
96cases玉・M・II至n・k・・dt’・kit）・Th・n・岬・・1・r・i・each ki・werc d・ter・nin・d・r b・1・w 2・5・g／ml
in Eiken’s kit， below 2．O ng／ml in Clinical Assays’ kit and 2．2 ng／ml in Mallinckrodt’s kit． From
the clinical point of view， PAP level below 2．5 to 3．0 pg／ml may be suitable for the normal value in
three kitsi．
    5） Other than the patients with prostatic carcinoma， there were three with B．P．H． whose PAP
rose above the normal level in Eiken’?kit． ln Cli ical Assays’ kit such patients were observed in
two with B．P．H． and one with nonprostatic diseases． There was only one patients．with B．P．H． whose
？AP rose above the ’normal level in Mallinckrodt’s kit． ln prostatic carcinoma， the positive rate
of PAP were 28．60／，， 37．50／， and 84．20／， in stage A十B， C and D， respectively in Eiken’s kit； 100／，，
45．50／． and 8 i．30／． in Clinical Assays’ kit； 42．90／．， 37．50／， and 1000／， in Mallinckrodt’s kit． The positive
rate of PAP in relation to．clinical stage could not be compared each other in three kits because these
patients were not identical． Adding up the ．samples of all the tests the positive rate was 22．60／o in
stage A十B， 37．10／． in C and 85．49／， in D． This value of stage A十B seems to be low．
   6） The sensitivity and the specificity were 53．30／， and 1000／，， respectively in PAP－RIA． ln
TAP－Enzyme assay thesc were 35．5％and 94．9％，respectively， in PAP－Enzyme assay the sensitivity was
48．6％and the speci且city 75．9％． These results have led us to． the conclusion that the radioimmuno一．
assay for PAP has given more accurate information in clinical practice than the enzyme assay ’?≠
done． Because of some advantage in the enzyme assay， however， the radioimmunoassay has been
required to be further improved in its procedure．
   7） The usefulness of radioimmunoassay for PAP in screening the patients with prostatic carcinoma
in early stage has not been established． Our results agreed with this Opinion． Not only more improve－
rr．）Nep－t of ra．d：ojrr．i－rr．i－unoassay for PAP but a！so elucidatinvn ef the mechanisrr．i． of I AP elpvvation in prostatic
carcinoma will be necessary for the establishment of the clinical usefulness of PAP for screeniRg of
early prositatic cancer．

















究所製RIA kit（以下Eiken kitと略す）， Clinical
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Table 1． Nurriber of cases and age distribution of maie and female subjects
          in the investigation of serum PAP
15






      kit
Ma11’inckrodt
      kit
Normal male subjects and





Patients with                 untreated
prostatic
carclnoma
                 treated
     75
 5 y．o．一82 y．o．
      33
56y．o．一ア9 y．o．
      17
13 y．o．一82 y．o．
      49
58 y．o．一80 y．o．
      16
63y．o．一ア8 y．o．
     57
 5 y．o．一82 y．o．
     25’
56 y．o．一78 y．o．
      7
28 y．o．一78 y．o．
     3ア
58 y．o．一80 y．o．
     15
63y．o．一ア8 y．o．
      34
20 y．o．一78 y．o．
      15
56 y．o．一ア8 y・o・
      13
13 y．o．一78 y．o．
      21
62 y．o．一82 y．o，
      13
63y．o．一フ8 y。o．
Total ］90 141 96
Table 2．RIA proce’р浮窒??in three kits
Standard or patfient serum
         十
Anti－PAP serum
       ラ
 ｛Incubation at room temparature）
       ラ
］25  1－labeled PAP
       量
 Uncubation at reom temparature）
       豊
Second antibody
       寺
 CIncubation at room temparature）
       畢
Centrifugation and aspiration of supernatant
      Eiken Clinical Assays MaHinckroclt
      O．］ nil ・O．1 ml O．2 ml
      O．2 ml O．］ ml O．1 ml
     20 hours 18 hours 2 hours
      O，2 ml OA ml B，2 ml
     20 hours 3 hours 2 － 24 hourg
      O．2 ml LO ml i，O ml
     30 minutes ’30 minutes O minutes
2000xg for 30 ninutes ］OOOxg for 20 minutes 2000× g for 20 minutes
                     ラ
Estimation of amoUnt of radioactivity with garmna counter
                     量
Determination of standard curve and PAP level in patient serum




















Eiken kitでは1．25 ng／ml， Clinical Assays kitでは






















  1．25 2 345 10 20ng／ml
       Standarci PAP
Fig． 1． Standard calibration curve of
    Eiken’s RIA kit
II ．結 果
 基礎的検討：1）標準曲線の再現性（Fig，1～3），































2 345 10 20 30 ng／ml
  Standard PAP
Standaird cali：bration curve ef




2 3  4  5 10 20 30 40 ng／ml
  Standard PAP
Standard calibration curve of
Mallinckrodt’s RIA kit







Reproducibility of Eiken’s kit within assay and between assays
17













































































 5）各kit間の関係（Fig，7，8）， Eiken kitの標準
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Reproducibility of Clinical Assays’ kit within assay
and between assays






























































＃ control serum 2．0 ng／ml
＃＃ control serum 12．0 ng／ra1
つた．






















2．5 ng／m1以下， Clinical Assays・ kitでは2・O ngfml
塚本・ほか：前立腺性酸性フォスファターゼ・RIA
Table 5．Reproducibility of Mellinckrodt’s kit within assay
and between assays
19















































1．8 6．8 14．3 33．3







































   1／16 1／4 1／2 1  1／8
        Dilution of serum
Fig． 4． Relation between measured PAP and



































































    1／16 1／4 1／2 1   1／8
         Dilution of serum
Fig． 5． Relation between measured PAP and the
























    1／16 1／4 1／2 1   1／8
         Dilution of serum
Fig． 6． Relation between measured PAP and the




と，stage A十Bでの陽性率は25．8％， C 40．0％， D
85．4％であった．
 次｝こPAP－RIA， enzyme assayでのscnsitivityと
speci丘cityとを比較検討する目的で各種疾患での
PAP－R1A（各kitでの測定検体を合計）， TAP－





















 enzyme assay lこよる酸性フォスファターゼの測
定には，phenyl ph◎sphate，α一glycerophosphate，β一
naphthylphosphate， p－nitrophenolphosphate， sodium








であるRIA， fluorescent immunoassay， counterimmu－
noelectrophoresisが開発されている，
 今回われわれが検討したEiken kit， Clinical Assays









Table 6． Recovery test in three kits
Expected valueRecovered valueRecoverv rate （OA
Eiken
kit




























































































oY ＝ 一1 ．O ＋ O．54xr ＝ O．994
10 20 30 40 ng／ml
PAP level measured by Clinical Assays （e） and MaMinckrodt （O） kit
  Fig． 7． Relation among three kits． Eikens’ standard． PAP were measured





























卜！allinckrodt  kit                                             ．
          N．D．  1－ 1．25 ＿ 1．5 ＿ 1．75 － 290 － 2．25 － 2．5 － 2．フ － 3．0 3．Ol一・一
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3 5 10 15 20
ng／ml
                       PAP in RIA
Fig， 9． Relation between PAP in RIA
       （一一一一一一一 normal range）
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1 5 1o ］5 20
ng／ml
                       PAP in RIA
Fig． 10． Relatibn of between PAP in RIA and
        （一一一一一一一 normal range）
TAP in Enzyme assay
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1 5 10 15 20
ng／ml
                           PAP うn RIA
Fig． 11． Relation between PAP in RIA and TAP in Enzyme assay
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Sample II （ 20．0 ng／rnl ）
  も＼＼
  ＼ ・
   、    、
    ＼ 、、
     、  o■r●晒■噂一〇
      ＼
       、       ’ls．．一一
           曜、層嘲◎
12
Time ｛ hours ）
PAP in RIA
48 12
Time （ hours ）
24
    ＠一’一（1） TAP in Enzyme assay O一一”O ’ PAP in Enzyme assay
Fig． 12． Infiuence of room temperature on PAP． RIA by Eiken’s kit and
        Enzyme assay by Kind－King’s procedure
           ’塚本・ほか：前立腺性酸性フォスファターゼ・RIA
Tabl・e 7． PAP ill normal subjects狐d the patients with urological diseases
                                                       （Mean±S．D． ng／ml）
25
RIA systems
Eiken kit Clinical Assays kitMallinckrodt kit
Group
Normal rnale subjects and
patients with non－prostaticdiseases
           5 一 19 y．o．
          20 一 49 y．o．






















Patients with B．P．H． 1．9 ± O．53 （n＝33） 1．4 ± O．68 （n＝25） 1．6 ± O．40 （n＝15）
Normal female subjects and
female pdtients







Eiken kit Clinical Assays kit
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      n＝33                           n＝25
Hg．13． Di・t・ibuti…fPAP｛・p・ti・・重・with B．P．H．（N．D．，
    Eikerl kit                Clinicdl Assays kit
                     ng／ml                      ng／m1
                     3．0                   3．0
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Distribution of PAP in the patients with non－prostatic diseases
         n＝15
not detected）
  Mallinckrodt kit
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stage B 79％， stage（〕71％， stage D 92％ときわめ
て高い成績であるが，Griffiths7）， Murphyら25），
Bruceら27）はstage A l 2～38％， stage B 29～35％，
stage C 24～49％， stage D 68～89％と報告してい
る（Table ll）・本邦では丸岡ら10），町田ら13）の報告が
あるが，前者ではstagc A十B 25％， stage G 50％，
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A B c D Well Relapsed
  centrol led status
  status
                         （N．D．：Not Detected）



















おける再現性をwithin assay， between assayで検討
しアこ．within assayにおいてはEiken kitでC．V．
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Fig． 18． Relation of PA［P level among three kits in the patients with’
        B．P．H．（e） and non－prostatic diseases（O） above twenty year old
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         コ      carc「lnoma
26／49 53．1 70’ 19／37 51．4 oA12／21 57．1 ％ 57／10753．3 ％
stage A ＆ B 4ハ4 28．6 Ol． 1／10 IO．o e％ 3／ 7 42．9瓢 8／31 25．8 ％
stage C 6／16 37．5 Ole 5／Y 45，5 ％ 3／ 8 37．5 ％ 14／35 40．o el，
stage D 16／19 84．2 O！． 13／16 81．3 70 6／ 6 1ae ele 35／ 41 85．4 Ole
’ positive cases in each kit ／ total cases in each kit
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Fig・i9・R・1・ゆb・twg・n PAP－RIA・叫TAP－Enrym・耳ssay in 31・ampl・・
        with tstage ．A and’B prostatic carcinoma
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Fig． 20．Relation between PAP－RIA and PAP－Enzyme assay in 31 samples in
stage A and B prostatic carcinoma
腺肥大症，前立腺以外の泌尿生殖器疾愚での測定値を










r ＝＝O．69， Clinical Assays kit： r＝＝O．85， Mallinckrodt
kit：r＝O・71），低濃度では相関は低下していた．
 4）正常男女成人，泌尿生殖器疾患男女症例（Eiken
kit：190例， Clinical Assays kit：141例， Mallinckrodt
kit：96例）において計427検体でPAPを測定した．
正常値はEiken kit 2・5 ng／ml以下， Clinical Assays














st ge A十B 22．6％， C 37・1％， D 85・4％であり， stage
A十Bでの陽性率は低かった．
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Relation between PAP－RIA and TAP－Enzyme assay in 85 samples with
stage C， and in 41 samples with stage D prostatic carcinoma
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Table 9． Sensitivity and specificity of PAP in RIA， and TAP and PAP in Enzyme assay
PAP一一RIA TAP－Enzyme assayPAP－Enzyme assay
Positive NegatavePositiveNegative PositiveNegative
Prostatic carcinoma


































































     Specificity
           （Positive or Negative sample number／Total sample number）
PAP－RIA＝53。3 ％ （57／107）， 丁AP－Enzyme assay＝35．5 ％ （38／107），  PAP－Enzyme as．say＝48．6 ％ （52／10ア）
PAP－RIA：100  ％ （79／ 79）， TAP－Enzyme assay：94．9 ％ （ア5／ ア9）， PAP－Enzyme assay：75．9 ％ （60／79）
        塚本・ほか：前立腺性酸性フォスファターゼ・RIA
Table 10． Source of PAP， methods of purification and normal range
Sources of PAP Methods of purification Normal ranges
  l． Prostatic fluid
     cooper et al 5） g’el filtratien s一 72
  2． Hypertrophic plostate gland
     森川ら16＞ 、ffi，ity， fi。， e．、h，，ge ch，。m，t。9，phy
                           and gel filtration O 一一 3
     Etten et ai i7） afiinity chromatography ・and
                           gel fil’tration
     choe et ai 2i） ion exchange and affinity
                           chromatography 2．5 － 24
                 22）     Vihko et al                           affinfity chromatography O 一 IO
  3． Malignant prostatic tfissues
     Lee et ai 15） affinlty， fion exchange chromatography
                           and gel filtration． 1．4一 9．8
  4． Seminal plasma
     “Gahan et al 23） iDn exchange chromatography o 一 8．1
Table 11． Elevated PAP in patients with prostatic carcinoma （96）
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